Antecedentes y relevancia

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Chemotherapy has been the mainstay of treatment and shifted from the adjuvant to neoadjuvant setting in early stage disease. Promising new agents are on the horizon.

Regulatory approval status of non-chemotherapy agents in the early stage TNBC setting (status 1 June 2023)